PepPool: SARS‑CoV‑2 (SNMO), human

Human PBMC from COVID-19 convalescent individuals (first two from the left from individuals previously confirmed COVID-19 positive with PCR, and third from the left from individual recovering from COVID-19 symptoms) and healthy control. Cells (350,000 cells/well) were incubated overnight in the absence or presence of the SARS-CoV-2 S N M O defined peptide pool in the presence of anti-CD28 mAb. The number of cells secreting IFN-γ was analyzed by ELISpot and counted using MabtechIRIS.

PepPool: SARS‑CoV‑2 (SNMO), human

3622-1

$510

Publications: 21

Documents

Questions?

Validated for our assays.

In stock

Delivery 4-9 business days

Shipping $0

Intended use

This peptide pool is intended for studying immune responses against SARS-CoV-2 (S, N, M, and O proteins) using immunoassays such as ELISpot, FluoroSpot, and flow cytometry. It induces cytokine secretion from antigen-specific human T cells. For research use only. Not for use in diagnostic procedures.

Serum/Plasma samples

Description
The SARS-CoV-2 (SNMO) defined peptide pool induces secretion of e.g., IFN-γ, IL-2, and granzyme B from human T cells. It contains 47 peptides from the human SARS-CoV-2 virus. The peptides are derived from the spike protein (S), nucleoprotein (N), membrane protein (M), and the open reading frame (ORF)-3a and ORF-7a proteins. The purity of the synthetic peptides range from 60-99%.

The peptide pool has been validated using human PBMC from COVID-19 convalescent individuals previously PCR-confirmed as SARS-CoV-2 positive.

Peptides included in the peptide pool are listed in the datasheet.

Recommendation

Product details

Product	PepPool: SARS-CoV-2 (SNMO), human
Application	T cell stimulation, ELISpot, FluoroSpot, Flow cytometry
Reactivity	Human
Supplied in	Lyophilized
Contents	Peptide pool with 47 peptides, 25 ug of each peptide. Supplied in one vial (lyophilized).

Shipping and Storage

Shipping	Shipped at ambient temperature.
Storage	Store at -20 °C or below upon receipt.

Human PBMC from COVID-19 convalescent individuals (first two from the left from individuals previously confirmed COVID-19 positive with PCR, and third from the left from individual recovering from COVID-19 symptoms) and healthy control. Cells (350,000 cells/well) were incubated overnight in the absence or presence of the SARS-CoV-2 S N M O defined peptide pool in the presence of anti-CD28 mAb. The number of cells secreting IFN-γ was analyzed by ELISpot and counted using MabtechIRIS.

Human PBMC from COVID-19 convalescent individuals (first two from the left from individuals previously confirmed COVID-19 positive with PCR, and third from the left from individual recovering from COVID-19 symptoms) and healthy control. Cells (350,000 cells/well) were incubated overnight in the absence or presence of the SARS-CoV-2 SNMO defined peptide pool in the presence of anti-CD28 mAb. The number of cells secreting IFN-γ and IL-2 was analyzed by FluoroSpot and counted using MabtechIRIS.